Startups

Treatments for genetic bleeding disorders.

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Seedtable Score

Score icon 52

Locations

Company Size

  • 1 - 11

Last Stage Round

Insights

Hemab, based in Copenhagen, shows strong potential with its focus on innovative treatments for genetic bleeding disorders. Their work addresses critical gaps in the market, where existing treatments often require frequent transfusions and result in high medical costs and reduced quality of life for patients. By developing more effective therapies, Hemab aims to improve patient outcomes and capture a substantial market share. Supported by investors like Novo A/S and HealthCap, Hemab is well-positioned to advance its research and introduce transformative therapies to a market in need of innovation.

Premium Member Intelligence

    Access details of the company management, and other intelligence on this company via Seedtable Intel